WO2009004339A3 - Modulation of reactive oxygen species in the treatment of respiratory infection - Google Patents
Modulation of reactive oxygen species in the treatment of respiratory infection Download PDFInfo
- Publication number
- WO2009004339A3 WO2009004339A3 PCT/GB2008/002280 GB2008002280W WO2009004339A3 WO 2009004339 A3 WO2009004339 A3 WO 2009004339A3 GB 2008002280 W GB2008002280 W GB 2008002280W WO 2009004339 A3 WO2009004339 A3 WO 2009004339A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- compositions
- relates
- oxygen species
- reactive oxygen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to therapeutic compositions for use in treating, ameliorating or preventing an infection such as a microbial infection in a subject, comprising a compound modulative of reactive oxygen species level, or CD200 level, or CD200R level, or a combination of two or more of said levels in said subject. The invention also relates to methods of treatment using such compositions. In addition, the invention relates to therapeutic compositions for use in treating, ameliorating or preventing an inflammatory pulmonary infection in a mammalian host having a CD200-CD200R axis comprising a compound modulative of said axis, and to methods of treatment using such compositions. Furthermore, the invention relates to therapeutic compositions for use in treating, ameliorating or preventing a microbial infection and/or pulmonary inflammation in a subject comprising a compound mimetic of superoxide dismutase, and to methods of treatment using such compositions.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95832907P | 2007-07-03 | 2007-07-03 | |
US60/958,329 | 2007-07-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009004339A2 WO2009004339A2 (en) | 2009-01-08 |
WO2009004339A3 true WO2009004339A3 (en) | 2009-10-22 |
Family
ID=39720324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2008/002280 WO2009004339A2 (en) | 2007-07-03 | 2008-07-03 | Compositions and methods relating to manipulation of the myeloid immune compartment during respiratory infection |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009004339A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3930687A4 (en) * | 2019-02-25 | 2023-06-07 | The University of Chicago | Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents |
GB2626300A (en) * | 2022-12-08 | 2024-07-24 | Ducentis Biotherapeutics Ltd | Mutated CD200 proteins and methods of use therof |
GB202303291D0 (en) * | 2023-03-07 | 2023-04-19 | Secr Defence | Medicament and medicament combination for use in the treatment of infectious disease |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030223991A1 (en) * | 2002-03-15 | 2003-12-04 | Cherwinski Holly M. | Methods of modulating CD200 receptors |
WO2004060295A2 (en) * | 2002-12-27 | 2004-07-22 | Schering Corporation | Methods of inducing and maintaining immune tolerance |
EP1616869A1 (en) * | 1999-01-25 | 2006-01-18 | National Jewish Medical and Research Center | Substituted porphyrins and their therapeutic use |
WO2007084321A2 (en) * | 2006-01-12 | 2007-07-26 | Alexion Pharmaceuticals, Inc. | Antibodies to ox-2/cd200 and uses thereof |
-
2008
- 2008-07-03 WO PCT/GB2008/002280 patent/WO2009004339A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1616869A1 (en) * | 1999-01-25 | 2006-01-18 | National Jewish Medical and Research Center | Substituted porphyrins and their therapeutic use |
US20030223991A1 (en) * | 2002-03-15 | 2003-12-04 | Cherwinski Holly M. | Methods of modulating CD200 receptors |
WO2004060295A2 (en) * | 2002-12-27 | 2004-07-22 | Schering Corporation | Methods of inducing and maintaining immune tolerance |
WO2007084321A2 (en) * | 2006-01-12 | 2007-07-26 | Alexion Pharmaceuticals, Inc. | Antibodies to ox-2/cd200 and uses thereof |
Non-Patent Citations (5)
Title |
---|
R. SNELGROVE, E. GWYER, T. HUSSELL: "Modulation of immunity to respiratory viral infection", FUTURE VIROLOGY, vol. 1, no. 4, July 2006 (2006-07-01), pages 471 - 481, XP001538706 * |
SNELGROVE ET AL.: "Manipulation of CD200 signalling offers therapeutic potential against respiratory infectious disease", IMMUNOLOGY, vol. 113, 2004, pages 5 - 7, XP002538514 * |
SNELGROVE R J ET AL: "In the absence of reactive oxygen species, T cells default to a Th1 phenotype and mediate protection against pulmonary Cryptococcus neoformans infection", JOURNAL OF IMMUNOLOGY 20061015 US, vol. 177, no. 8, 15 October 2006 (2006-10-15), pages 5509 - 5516, XP009105538, ISSN: 0022-1767 * |
SNELGROVE ROBERT J ET AL: "A critical function for CD200 in lung immune homeostasis and the severity of influenza infection", NATURE IMMUNOLOGY, NATURE PUBLISHING GROUP, GB, vol. 9, no. 9, 27 July 2008 (2008-07-27), pages 1074 - 1083, XP009105540, ISSN: 1529-2908, [retrieved on 20080727] * |
SNELGROVE ROBERT J ET AL: "An absence of reactive oxygen species improves the resolution of lung influenza infection.", EUROPEAN JOURNAL OF IMMUNOLOGY JUN 2006, vol. 36, no. 6, June 2006 (2006-06-01), pages 1364 - 1373, XP002495187, ISSN: 0014-2980 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009004339A2 (en) | 2009-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008133663A3 (en) | Codon modified immunogenic compositions and methods of use | |
MX2012009088A (en) | Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor. | |
WO2007075439A3 (en) | Compositions and methods for treating obesity and related metabolic disorders | |
WO2008051689A3 (en) | Nitric oxide-blocked cross-linked tetrameric hemoglobin | |
WO2007104792A3 (en) | Recombinant adenoviruses based on serotype 26 and 48, and use thereof | |
WO2008089268A3 (en) | Methods and compositions for treating conditions associated with infection and/or inflammation | |
MX2011011768A (en) | Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both. | |
MX2012004551A (en) | Novel compositions for preventing and/or treating lysosomal storage disorders. | |
IN2012DN00624A (en) | ||
WO2010036395A3 (en) | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds | |
WO2007141274A3 (en) | Human binding molecules having killing activity against staphylococci and uses thereof | |
WO2007082068A3 (en) | Methods and compositions for treating asthma in human and non human primates | |
WO2006050058A3 (en) | Methods of detection and therapy of inflamed tissues using immune modulation | |
WO2007143090A3 (en) | Hepatocyte growth factor (hgf) binding proteins | |
WO2006124892A3 (en) | Modulators of alpha-synuclein toxicity | |
WO2007127273A3 (en) | Methods and compositions for altering cell function | |
WO2007146730A3 (en) | Deacetylase inhibitor therapy | |
WO2014027965A8 (en) | Wound dressing nanomesh impregnated with human umbilical cord wharton's jelly stem cells | |
WO2014086764A3 (en) | Composition comprising a biological control agent and a fungicide | |
WO2011159840A3 (en) | Phenylthioacetate compounds, compositions and methods of use | |
WO2009077471A3 (en) | Azolylmethyloxiranes, use thereof and agents containing the same | |
WO2007146983A3 (en) | Compositions comprising tegaserod alone or in combination with a proton pump inhibitor for treating or preventing gastric injury | |
WO2009070693A3 (en) | Modulators of ocular oxidative stress | |
WO2008132021A3 (en) | Fungicide mixtures | |
WO2010077339A3 (en) | β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08775830 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08775830 Country of ref document: EP Kind code of ref document: A2 |